



## Homocysteine, B-vitamins and CVD

McNulty, H., Pentieva, K., Hoey, L., & Ward, M. (2008). Homocysteine, B-vitamins and CVD. *PROCEEDINGS OF THE NUTRITION SOCIETY*, 67(2), 232-237. <https://doi.org/10.1017/S0029665108007076>

[Link to publication record in Ulster University Research Portal](#)

**Published in:**  
PROCEEDINGS OF THE NUTRITION SOCIETY

**Publication Status:**  
Published (in print/issue): 01/05/2008

**DOI:**  
[10.1017/S0029665108007076](https://doi.org/10.1017/S0029665108007076)

**Document Version**  
Publisher's PDF, also known as Version of record

**General rights**  
Copyright for the publications made accessible via Ulster University's Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**  
The Research Portal is Ulster University's institutional repository that provides access to Ulster's research outputs. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact [pure-support@ulster.ac.uk](mailto:pure-support@ulster.ac.uk).

*The Summer Meeting of the Nutrition Society, hosted by the Irish Section, was held at the University of Ulster, Coleraine on 16–19 July 2007*

## Symposium on ‘Diet and CVD’

### Homocysteine, B-vitamins and CVD

Helene McNulty\*, Kristina Pentieva, Leane Hoey and Mary Ward

*Northern Ireland Centre for Food and Health (NICHE), School of Biomedical Sciences, University of Ulster, Coleraine BT52 1SA, UK*

There is considerable interest in plasma homocysteine (tHcy) as a CVD risk factor. Although the secondary prevention trials published to date have been inconclusive in confirming a benefit of tHcy-lowering treatment with B-vitamins on CVD events generally, such studies are widely recognised to have been insufficiently powered to detect a significant effect for the predicted magnitude of association between tHcy and heart disease risk, and therefore cannot be interpreted as evidence that no relationship exists. In fact, a recent meta-analysis of clinical trials has confirmed that folic acid supplementation reduces the risk of stroke, particularly in individuals without a history of stroke. Evidence supporting a causal relationship between elevated tHcy and heart disease also comes from genetic studies. The most important genetic determinant of tHcy in the general population is the common C677T variant in methylenetetrahydrofolate reductase (MTHFR) that results in higher tHcy. Individuals with the homozygous mutant (TT) genotype have a significantly higher (14–21%) risk of heart disease. Plasma tHcy is very responsive to intervention with the B-vitamins required for its metabolism, in particular folic acid, and to a lesser extent vitamins B<sub>12</sub> and B<sub>6</sub>. Thus, although primarily aimed at reducing neural-tube defects, folic acid fortification may have an important role in the primary prevention of CVD via tHcy lowering. Besides folate, riboflavin is required as a cofactor for MTHFR and enhanced riboflavin status results in a marked lowering in tHcy specifically in individuals with the TT genotype, presumably by neutralising the variant form of the enzyme. About 10% of the UK and Irish populations have the TT genotype. In the present paper the potential role of folate and related B-vitamins in the primary prevention of CVD and the implications for nutrition policy are explored.

#### B-vitamins: Folate: Homocysteine: CVD

##### Elevated homocysteine as a risk factor for CVD

Evidence from numerous prospective and retrospective case-control studies has emerged in recent years to link elevated plasma homocysteine (tHcy) levels with an increased risk of CVD. Meta-analyses of prospective studies have predicted that lowering tHcy by 3 µmol/l (or a reduction of 25% based on an average tHcy of 12 µmol/l) would reduce the risk of heart disease by 11–16% and stroke by 19–24%<sup>(1,2)</sup>. Although none of the secondary prevention trials published in more recent years have been able to confirm the benefit of tHcy-lowering therapy on CVD events generally<sup>(3–5)</sup>, it should not be assumed that

no relationship exists. It is now generally recognised that these trials lacked sufficient statistical power to detect an effect for the predicted magnitude of association between tHcy and heart disease<sup>(6)</sup>. In support of this viewpoint, a clear benefit in reducing stroke was shown in one of the previously mentioned ‘negative’ trials, although this result was not explicit in the conclusions<sup>(4)</sup>. Moreover, evidence just published from a meta-analysis of clinical trials in relation to stroke outcome has confirmed that folic acid supplementation reduces the risk of stroke by 18% overall, by 29% in trials with a treatment duration of >36 months and by 25% in those trials involving individuals without a history of stroke<sup>(7)</sup>. Such evidence is consistent with the

**Abbreviations:** MTHFR, methylenetetrahydrofolate reductase; tHcy, plasma homocysteine.

**\*Corresponding author:** Professor Helene McNulty, fax +44 28 7032 4965, email h.mculty@ulster.ac.uk

findings of a population-based study that has shown that the temporal decline in stroke-related mortality in the USA and Canada coincided with the introduction of folic acid fortification<sup>(8)</sup>. Thus, the case for tHcy as a risk factor in CVD is stronger for stroke than for heart disease, and possibly strongest for the primary prevention of stroke.

Another important line of evidence supporting a causal relationship between elevated tHcy and heart disease comes from genetic studies. The common C677T variant in the gene coding for the folate-metabolising enzyme methylenetetrahydrofolate reductase (MTHFR) is the most important genetic determinant of tHcy in the general population. The homozygous mutant TT genotype for the MTHFR C677T polymorphism typically affects about 10% of individuals worldwide but can be as high as 26% (southern Italy) and 32% (Mexico) in some areas<sup>(9)</sup>. MTHFR is required for the formation of 5-methyltetrahydrofolate, which in turn is required to convert homocysteine to methionine. Individuals with the TT genotype have reduced MTHFR activity, which results in impaired folate metabolism and elevated tHcy levels<sup>(10)</sup>. Three recent meta-analyses involving >25 000 cases have examined the impact on heart disease risk of this genetic variant and have shown an overall significantly higher (14–21%) risk of heart disease in individuals with this polymorphism as compared with those without this polymorphism<sup>(2,11,12)</sup>. The trend toward increasing risk of disease among individuals with no (CC genotype), one (CT genotype) or two copies (TT genotype) of the defective gene is consistent with the increasing gradient in tHcy typically found among the three genotypes (as would be expected if there is a causal relationship between elevated tHcy and risk of disease). However, analysis of the OR among countries shows a large geographical variation in the association between this polymorphism and heart disease risk<sup>(11,12)</sup>.

### Homocysteine-lowering with B-vitamins

The B-vitamins folate, vitamin B<sub>12</sub> and vitamin B<sub>6</sub> are required for homocysteine metabolism and several studies have examined their potential to lower tHcy.

#### Folate

Folate, the focus of much current debate on food fortification worldwide, is the major determinant of tHcy. The first meta-analysis to assess the tHcy-lowering effect of folic acid has concluded that doses in the range of 0.5 to 5 mg/d could lower tHcy by about 20–25%<sup>(13)</sup>. The effect of doses <0.5 mg/d is much less clear but is arguably the more relevant question for emerging food fortification policy. Some earlier evidence has suggested that doses in the range of 0.2–0.4 mg/d can achieve a maximum reduction in tHcy in young healthy populations<sup>(14,15)</sup>, while another study has shown that doses as high as 0.8 mg folic acid/d are required for maximal lowering of tHcy in those individuals with established heart disease<sup>(16)</sup>. Similarly, a meta-analysis of twenty-five randomised trials involving 2596 subjects (both healthy and patient groups) has concluded that a daily dose of 0.8 mg/d is required to achieve

a maximal reduction in tHcy, while doses of 0.2 and 0.4 mg/d are associated with only 60 and 90% of this maximal effect respectively<sup>(17)</sup>. However, one limitation of the latter meta-analysis is treatment duration; of the twenty-five studies examined the treatment in eighteen was of ≤8 weeks duration, six were of 12 weeks duration and only one was of long-term duration (i.e. 6 months). Some preliminary evidence suggests that longer treatment duration may be necessary to allow a complete tHcy-lowering effect to be observed in response to the lower doses of folic acid<sup>(18)</sup>. In addition, details on subject compliance were rarely reported in the original studies that examined the effect of different doses<sup>(17)</sup>, but this information is critical to the interpretation of the results because incomplete compliance by participants may result in an underestimation of the full extent of the tHcy response to a given dose. Food fortification, unlike supplementation, automatically provides maximal participant compliance; therefore, ensuring high subject compliance to the treatments should be a key aspect of any dose-finding study aimed at developing food fortification policies for the prevention of CVD.

Thus, some published reports may have overestimated the folic acid dose required to achieve maximal tHcy lowering, because of either incomplete or unmonitored subject compliance or, more importantly, an intervention period that was too short to observe the full extent of the tHcy response to lower folic acid doses in the range 0.2–0.4 mg/d. Clearly, the issue as to the lowest dose of folic acid associated with a maximum reduction in tHcy remains controversial and requires further investigation, especially in light of recent reports that highlight potential adverse effects of overexposure to higher intakes of folic acid<sup>(19,20)</sup>.

#### Vitamin B<sub>12</sub>

In addition to folate, the enzyme methionine synthase involved in the remethylation of homocysteine to methionine requires vitamin B<sub>12</sub> as cofactor. Although a number of studies in healthy populations and in patients have investigated the effect of various doses of folic acid supplementation in lowering tHcy, few have examined the independent effects of vitamin B<sub>12</sub>. In those studies that have administered low-dose vitamin B<sub>12</sub> as a separate treatment, the response of vitamin B<sub>12</sub> biomarkers was the primary outcome and the tHcy response was measured as a secondary objective<sup>(21,22)</sup>. Furthermore, the study populations were selected for mild vitamin B<sub>12</sub> deficiency and were not pretreated with folic acid before vitamin B<sub>12</sub> supplementation. Of even greater importance, vitamin B<sub>12</sub> was not administered with food, the presence of which is required to stimulate the normal vitamin B<sub>12</sub> absorptive mechanisms. The tHcy-lowering response observed may therefore have been confounded by differences in folate status or an incomplete absorption of the administered dose.

The reason for the limited number of intervention studies with vitamin B<sub>12</sub> is that this vitamin is generally considered to be a far-less-effective determinant of tHcy concentrations compared with folate. However, evidence from a study of healthy subjects supplemented with

low-dose folic acid<sup>(23)</sup> and from studies in the era of mandatory folic acid fortification of cereal grains in the USA<sup>(24–26)</sup> shows that vitamin B<sub>12</sub> becomes the main nutritional determinant of tHcy once folate status is optimised. Furthermore, meta-analyses of intervention studies that have examined the effect of B-vitamins on tHcy lowering have shown that including vitamin B<sub>12</sub> along with folate produces an additional one-third (7%) lowering of tHcy above that achieved with folate alone (typically 25% lowering<sup>(13,17)</sup>). As the relationship between tHcy and CVD is graded, any small but significant further decrease in tHcy concentrations could be predicted to confer an additional benefit in terms of CVD risk. Although the results of the randomised clinical trials published so far are disappointing in that they have failed to show a benefit of tHcy-lowering therapy on CVD events generally, re-analysis of data from the negative Vitamin Intervention for Stroke Prevention trial<sup>(3)</sup> has shown the importance of vitamin B<sub>12</sub> in relation to tHcy and CVD risk. When subjects who were considered to receive no benefit from vitamin therapy were excluded (i.e. patients believed to be on vitamin B<sub>12</sub> supplements and patients with renal failure), the group receiving the high-dose therapy were found to have a 21% reduced risk of CVD events compared with the low-dose group<sup>(27)</sup>. Those patients with higher baseline vitamin B<sub>12</sub> levels who received the high-dose B-vitamin therapy during intervention were shown to have the best outcome for survival free of a CVD event<sup>(27)</sup>. Thus, the inclusion of vitamin B<sub>12</sub> along with folic acid may be a more effective therapy for reducing the risk of CVD via tHcy lowering than folic acid alone. Such a therapy could be of particular benefit to older adults, as suboptimal vitamin B<sub>12</sub> status (mostly as a result of food-bound vitamin B<sub>12</sub> malabsorption) is highly prevalent<sup>(28)</sup> and CVD is a common cause of morbidity and mortality in this subgroup of the population. However, further supplementation studies with vitamin B<sub>12</sub> are required to determine the optimal dose for lowering tHcy.

#### *Vitamin B<sub>6</sub>*

The transsulfuration of homocysteine to cysteine by cystathionine  $\beta$ -synthase requires vitamin B<sub>6</sub> (pyridoxal phosphate) as a cofactor, and studies have considered the potential of vitamin B<sub>6</sub> to lower tHcy. Although the literature generally suggests either that vitamin B<sub>6</sub> does not have a tHcy-lowering effect<sup>(13,17)</sup> or that it lowers tHcy only in exceptional circumstances (e.g. in pyridoxine-responsive homocystinuria or in patients with severe vitamin B<sub>6</sub> deficiency), there is some evidence of a small but significant tHcy response (lowered by 7.5%) to low-dose vitamin B<sub>6</sub><sup>(29)</sup>. However, the latter intervention was conducted in healthy older subjects whose status of both folate and riboflavin was optimised before intervention with vitamin B<sub>6</sub>; this study design may explain why a significant tHcy response was observed in this study but not in other studies<sup>(13,17)</sup>.

Apart from its role in homocysteine metabolism, vitamin B<sub>6</sub> is also required for the metabolism of *n*-3 PUFA<sup>(30)</sup>. Thus, independently of any tHcy-lowering effect, some studies have investigated the potential ability of vitamin B<sub>6</sub>

to suppress some of the underlying mechanisms involved in the atherosclerotic process such as platelet aggregation<sup>(31)</sup> and the proliferation of endothelial cells<sup>(32)</sup>. The findings so far from various studies are inconsistent. The results from the Nurses' Health Study of 80 000 women followed for 14 years have demonstrated that a higher dietary intake of vitamin B<sub>6</sub> (i.e. >3 mg/d) is associated with a decreased risk of heart disease<sup>(33)</sup>. Furthermore, retrospective and prospective case-control studies have related low plasma concentrations of vitamin B<sub>6</sub>-status indices to increased risk of stroke, peripheral vascular disease and coronary artery disease<sup>(34–37)</sup>. However, after adjusting for established CVD risk factors the relationship between vitamin B<sub>6</sub> indices and CVD in some of these studies was found to be no longer significant<sup>(34,38)</sup>. More-recent investigations have reported that low vitamin B<sub>6</sub> status is related to chronic inflammation<sup>(39)</sup>, which in turn is known to promote atherosclerosis and the development of CVD. This finding might suggest that low vitamin B<sub>6</sub> status is not an independent risk factor for CVD and stroke but merely a marker of chronic inflammation. Evidence as to whether low vitamin B<sub>6</sub> status is a causal factor for CVD can only be provided by controlled intervention studies. So far, the results of four randomised controlled trials that included vitamin B<sub>6</sub> supplementation (as an independent treatment or in combination with folic acid and vitamin B<sub>12</sub>) for  $\leq 5$  years in patients with pre-existing CVD have been published, but they have failed to detect any impact of vitamin B<sub>6</sub> on the risk of a recurrent cardiovascular event<sup>(40)</sup>. However, it is widely acknowledged that these trials were underpowered, and even after combining them it appears that there is insufficient power to detect a significant effect on the risk of CVD<sup>(40)</sup>. Moreover, the doses of vitamin B<sub>6</sub> used in these trials were pharmacological levels (40 mg/d), the long-term effects of which remain unknown. Finally, these trials were conducted in individuals with pre-existing disease and it is not known whether vitamin B<sub>6</sub> would have a role in the primary prevention of CVD. Carefully-designed and sufficiently-powered long-term intervention studies examining the effect on CVD of low doses of vitamin B<sub>6</sub> (within the dietary range) are clearly warranted.

#### **Gene–nutrient interactions**

The typical phenotype associated with homozygosity for the MTHFR C677T polymorphism is elevated tHcy levels<sup>(10)</sup>. Individuals with the TT genotype are considered to have increased dietary folate requirements on the basis that they have lower erythrocyte folate levels compared with those without this genetic variant<sup>(41)</sup>, and the increase in tHcy is found to be most marked among those with lower folate status<sup>(42,43)</sup>.

A fourth, much overlooked, B-vitamin is also involved in homocysteine metabolism. In addition to folate, riboflavin (in its co-enzymic form FAD) is required as a cofactor for the MTHFR enzyme. The reduced activity of the MTHFR 677TT variant of MTHFR has been shown to result from the inappropriate loss of its FAD cofactor<sup>(44)</sup>. Observational studies in human subjects that have



investigated the relationship between riboflavin status and tHcy in individuals with different MTHFR genotypes have reported somewhat inconsistent results<sup>(45–47)</sup>. In the USA an association between riboflavin status and tHcy has been reported in individuals with the TT genotype in the Framingham Cohort<sup>(45)</sup>, but this association is confined only to those with the TT genotype and low folate status; thus, riboflavin does not seem to be the limiting nutrient. The two studies conducted in healthy European populations (Norway and Northern Ireland), however, have both identified riboflavin as an important determinant of tHcy among individuals with the TT genotype and have indicated that this effect is not explained by folate<sup>(46,47)</sup>. The inconsistency between studies is probably explained by the mandatory fortification of flour with riboflavin in the USA, which would have the effect of optimising riboflavin status in the general US population, thereby reducing the extent to which riboflavin is found to be a limiting nutrient in determining tHcy levels in individuals with the TT genotype. Recent results that show a genotype-specific response of tHcy to riboflavin supplementation now confirm that riboflavin is an independent modifier of tHcy in individuals with the TT genotype. Significant lowering of tHcy in response to riboflavin supplementation was observed in healthy individuals with the TT genotype, with levels decreasing by as much as 22% overall, and markedly so (by 40%) in those with lower riboflavin status at baseline<sup>(48)</sup>. No tHcy response to intervention was observed in those with CC or CT genotypes, despite a significant improvement in riboflavin status in both cases and the pre-selection of subjects with suboptimal riboflavin status at baseline. The lack of a tHcy-lowering effect of riboflavin in the absence of this polymorphism was observed previously, in an earlier intervention study of healthy elderly individuals who were also pre-screened for suboptimal riboflavin status but not for MTHFR genotype<sup>(49)</sup>. The responsiveness of tHcy to riboflavin is therefore specific to individuals with the MTHFR 677TT genotype and represents a new gene–nutrient interaction.

The inconsistencies in the literature as to whether the MTHFR C677T polymorphism is associated with a higher risk of heart disease may also relate to the role of riboflavin. Although meta-analyses have reported an overall 14–21% higher risk of heart disease in individuals with the TT genotype<sup>(2,11,12)</sup>, analysis of the OR between continents shows that the excess heart disease risk associated with this polymorphism is significant in Europe but not in North America. This geographical variation is generally assumed to be the result of differences in folate status<sup>(11,12)</sup>, while riboflavin, the cofactor for MTHFR, is generally overlooked as a potential modulator of the disease risk associated with this polymorphism. However, the policy of mandatory riboflavin fortification has existed for >50 years in the USA, and given the marked genotype-specific decrease in tHcy with riboflavin intervention<sup>(48)</sup>, it is not unreasonable to suggest that it might also modulate heart disease risk in this subpopulation with genetic predisposition to elevated tHcy. Thus, the reported differences among countries as to whether this polymorphism represents an increased risk of heart disease may relate not only to differences in folate as commonly suggested<sup>(11,12)</sup>, but

also to differences in the prevailing riboflavin status. It could be predicted that individuals with the TT genotype who also have low riboflavin status would have an excess risk of heart disease, whereas with optimal riboflavin status they would not carry the expected risk. Notably, support for this viewpoint is offered by very recent evidence of higher blood pressure at baseline and a marked lowering of both systolic and diastolic blood pressure in response to riboflavin intervention specifically in patients with the TT genotype<sup>(50)</sup>.

### Implications for nutrition policy

Folate is the major determinant of tHcy. As has been experienced in the USA since its introduction<sup>(51)</sup>, there is no doubt that folic acid fortification, if introduced in a population, would have a major tHcy-lowering effect irrespective of genotype. Vitamins B<sub>12</sub> and B<sub>6</sub> also play key roles in homocysteine metabolism, with evidence showing that both vitamins may be important determinants of tHcy, particularly when folate status has been optimised<sup>(23,24,29)</sup>. Thus, all three vitamins could arguably be included in any fortification policy aimed at lowering tHcy in the general population, with potential benefits in preventing CVD and possibly stroke in particular<sup>(7)</sup>. Emerging food policy in different countries should also consider the riboflavin requirements of individuals homozygous for the common MTHFR C677T polymorphism. Riboflavin status appears to be a potent modulator of the expected (high tHcy) phenotype among individuals with the TT genotype. Of greater importance, new evidence shows marked lowering of blood pressure in response to riboflavin intervention specifically in patients with the TT genotype, which may or may not be independent of the tHcy-lowering effect of riboflavin also seen only in the TT genotype<sup>(48,50)</sup>. Importantly, the fact that these effects of riboflavin are achievable with a very modest increase in riboflavin intake (1.6 mg/d) suggests that there are important implications for dietary riboflavin requirements in individuals with this common genetic variant and for food-fortification policy aimed at the primary prevention of CVD. In order to cover the needs of appreciable subgroups (3–32%) of populations worldwide with this genotype<sup>(7)</sup> riboflavin may need to be considered for inclusion together with folic acid in fortification programmes under discussion.

### References

1. Homocysteine Studies Collaboration (2002) Homocysteine and risk of ischemic heart disease and stroke. *JAMA* **288**, 2015–2022.
2. Wald DS, Law M & Morris JK (2002) Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. *Br Med J* **325**, 1202–1208.
3. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides EG, Wang CH & Stampfer M (2004) Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction and death: The Vitamin Intervention for Stroke Prevention (VISP) Randomized Controlled Trial. *JAMA* **291**, 565–575.

4. The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators (2006) Homocysteine lowering with folic acid and B vitamins in vascular disease. *N Engl J Med* **354**, 1567–1577.
5. Bona KH, Njølstad I, Ueland PM *et al.* (2006) Homocysteine lowering and cardiovascular events after acute myocardial infarction. *N Engl J Med* **354**, 1629–1632.
6. B-Vitamin Treatment Trialists' Collaboration (2006) Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials. *Am Heart J* **151**, 282–287.
7. Wang X, Qin X, Demirtas H, Li J, Mao G, Huo Y, Sun N, Liu L & Xu X (2007) Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. *Lancet* **369**, 1876–1882.
8. Yang Q, Botto LD, Erickson JD, Berry RJ, Sambell C, Johansen H & Friedman JM (2006) Improvement in stroke mortality in Canada and the United States, 1990 to 2002. *Circulation* **113**, 1335–1343.
9. Wilcken B, Bamforth F, Li Z *et al.* (2003) Geographical and ethnic variation of the 677C>T allele of 5,10 methylenetetrahydrofolate reductase (MTHFR): findings from over 7000 newborns from 16 areas world wide. *J Med Genet* **40**, 619–625.
10. Frosst P, Blom HJ, Milos R *et al.* (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. *Nat Genet* **10**, 111–113.
11. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ & Schouten EG (2003) MTHFR 677C→T polymorphism and risk of coronary heart disease: a meta-analysis. *JAMA* **288**, 2023–2031.
12. Lewis SJ, Ebrahim S & Davey Smith G (2005) Meta-analysis of MTHFR 677C→T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate. *Br Med J* **331**, 1053–1056.
13. Homocysteine Lowering Trialists' Collaboration (1998) Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomized trials. *Br Med J* **316**, 894–898.
14. Ward M, McNulty H, McPartlin J, Strain JJ, Weir DG & Scott JM (1997) Plasma homocysteine, a risk factor for cardiovascular disease, is lowered by physiological doses of folic acid. *QJM* **90**, 519–524.
15. Daly S, Mills JL, Molloy AM, Conley M, McPartlin J, Lee YJ, Young PB, Kirke PN, Weir DG & Scott JM (2002) Low-dose folic acid lowers plasma homocysteine levels in women of child-bearing age. *QJM* **95**, 733–740.
16. Wald DS, Bishop L, Wald NJ, Law M, Hennessy E, Weir D, McPartlin J & Scott J (2001) Randomized trial of folic acid supplementation and serum homocysteine levels. *Arch Intern Med* **161**, 695–700.
17. Homocysteine Lowering Trialists' Collaboration (2005) Dose-dependant effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials. *Am J Clin Nutr* **82**, 806–812.
18. Tighe P, Ward M, McNulty H, Finnegan O, Strain JJ, Dunne A, Molloy AM & Scott JM (2004) Plasma homocysteine response to folic acid intervention in ischaemic heart disease patients: implications for food fortification policy. *Proc Nut Soc* **63**, 51A.
19. Troen AM, Mitchell B, Sorensen B *et al.* (2006) Unmetabolized folic acid in plasma is associated with reduced natural killer cell cytotoxicity among postmenopausal women. *J Nutr* **136**, 189–194.
20. Cole BF, Baron JA, Sandler RS *et al.* (2007) Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. *JAMA* **297**, 2351–2359.
21. Seal EC, Metz J, Flicker L & Melny J (2002) A randomized, double-blind, placebo-controlled study of oral vitamin B12 supplementation in older patients with subnormal or borderline serum vitamin B12 concentrations. *J Am Geriatr Soc* **50**, 146–151.
22. Eussen SJPM, De Groot LCPGM, Clarke R, Schneede J, Ueland PM, Hoefnagels WHL & van Staveren WA (2005) Oral cyanocobalamin supplementation in older people with vitamin B12 deficiency. *Arch Intern Med* **165**, 1167–1172.
23. Quinlivan EP, McPartlin J, McNulty H, Ward M, Strain JJ, Weir DG & Scott JM (2002) Importance of both folic acid and vitamin B-12 in reduction of risk of vascular disease. *Lancet* **359**, 227–228.
24. Liaugaudas G, Jacques PF, Selhub J, Rosenberg IH & Boston AG (2001) Renal insufficiency, vitamin B-12 status, and population attributable risk for mild hyperhomocysteinemia among coronary artery disease patients in the era of folic acid-fortified cereal grain flour. *Arterioscler Thromb Vasc Biol* **21**, 849–851.
25. Johnson MA, Hawthorne NA, Brackett WR, Fischer JG, Gunter EW, Allen RH & Stabler SP (2003) Hyperhomocysteinemia and vitamin B-12 deficiency in elderly using Title IIIc nutrition services. *Am J Clin Nutr* **77**, 211–220.
26. Robertson J, Lemolo F, Stabler SP, Allen RH & Spence JD (2005) Vitamin B12, homocysteine and carotid plaque in the era of folic acid fortification of enriched cereal grain products. *Can Med Assoc J* **172**, 1569–1573.
27. Spence JD, Bang H, Chambless LE & Stampfer MJ (2005) Vitamin intervention for stroke prevention trial: an efficacy analysis. *Stroke* **36**, 2404–2409.
28. Wolters M, Strohle A & Hahn A (2004) Cobalamin: a critical vitamin in the elderly. *Prev Med* **39**, 1256–1266.
29. McKinley MC, McNulty H, McPartlin J, Strain JJ, Pentieva K, Ward M, Weir DG & Scott JM (2001) Low-dose vitamin B-6 effectively lowers fasting plasma homocysteine levels in healthy elderly persons who are folate and riboflavin replete. *Am J Clin Nutr* **73**, 759–764.
30. Tsuge H, Hotta N & Hayakawa T (2000) Effect of vitamin B6 on (n-3) polyunsaturated fatty acid metabolism. *J Nutr* **130**, Suppl., 333S–334S.
31. Chang SJ, Chang CN & Chen CW (2002) Occupancy of glycoprotein IIb/IIIa by B6 vitamers inhibit human platelet aggregation. *J Nutr* **132**, 3603–3606.
32. Matsubara K, Matsumoto H, Mizuchina Y, Lee JS & Kato N (2003) Inhibitory effect of pyridoxal 5'-phosphate on endothelial cell proliferation, replicative DNA polymerase and DNA topoisomerase. *Int J Mol Med* **12**, 51–55.
33. Rimm EB, Willett WC, Hu FB, Sampson L, Colditz GA, Manson JE, Hennekens C & Stampfer MJ (1998) Folate and vitamin B6 from diet and supplements in relation to risk in coronary heart disease among women. *JAMA* **279**, 359–364.
34. Chasan-Taber L, Selhub J, Rosenberg IH, Malinow MR, Terry P, Tishler PV, Willett W, Hennekens CH & Stampfer MJ (1996) A prospective study of folate and vitamin B6 and risk of myocardial infarction in US physicians. *J Am Coll Nutr* **15**, 136–143.
35. Robinson K, Arheart K, Refsum H *et al.* (1998) Low circulating folate and vitamin B6 concentrations: risk factors for stroke, periphery vascular disease, and coronary vascular disease. European COMAC group. *Circulation* **97**, 437–443.
36. Folsom AR, Nieto FJ, McGovern PG, Tsai MY, Malinow MR, Eckfeldt JH, Hess DL & Davis CE (1998) Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study. *Circulation* **98**, 204–210.
37. Kelly PJ, Shih VE, Kistler JP, Barron M, Lee H, Mandell R & Furie KL (2003) Low vitamin B6 but not homocyst(e)ine is associated with increased risk of stroke and transient

- ischemic attack in the era of folic acid grain fortification. *Stroke* **34**, e51–e54.
38. Kelly PJ, Kistler JP, Shih VE, Mandell R, Atassi N, Barron M, Lee H, Silveira S & Furie KL (2004) Inflammation, homocysteine and vitamin B6 status after ischemic stroke. *Stroke* **35**, 12–15.
  39. Friso S, Jacques PF, Wilson PWF, Rosenberg IH & Selhub J (2001) Low circulating vitamin B6 is associated with elevation of the inflammation marker C-reactive protein independently of plasma homocysteine levels. *Circulation* **103**, 2788–2791.
  40. Clarke R, Lewington S, Sherliker P & Armitage J (2007) Effects of B-vitamins on plasma homocysteine concentrations and on risk of cardiovascular disease and dementia. *Curr Opin Clin Nutr Metab Care* **10**, 32–39.
  41. Molloy AM, Daly S, Mills JL, Kirke PN, Whitehead AS, Ramsbottom D, Conley MR, Weir DG & Scott JM (1997) Thermolabile variant of 5,10-methylenetetrahydrofolate reductase associated with low red-cell folates: implications for folate intake recommendations. *Lancet* **349**, 1591–1593.
  42. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, Selhub J & Rozen R (1996) Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. *Circulation* **93**, 7–9.
  43. Brattström L, Wilcken DEL, Ohrvik J & Brudin L (1998) Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease – the result of a meta-analysis. *Circulation* **98**, 2520–2526.
  44. Yamada K, Chen Z, Rozen R & Matthews RG (2001) Effects of common polymorphisms on the properties of recombinant human methylenetetrahydrofolate reductase. *Proc Natl Acad Sci USA* **98**, 14853–14858.
  45. Jacques PF, Kalmbach R, Bagley PJ, Russo GT, Rogers G, Wilson PW, Rosenberg IH & Selhub J (2002) The relationship between riboflavin and plasma total homocysteine in the Framingham Offspring cohort is influenced by folate status and the C677T transition in the methylenetetrahydrofolate reductase gene. *J Nutr* **132**, 283–288.
  46. Hustad S, Ueland PM, Vollset SE, Zhang Y, Bjorke-Monsen AL & Schneede J (2000) Riboflavin as a determinant of plasma total homocysteine: effect modification by the methylenetetrahydrofolate reductase C677T polymorphism. *Clin Chem* **46**, 1065–1071.
  47. McNulty H, McKinley MC, Wilson B, McPartlin J, Strain JJ, Weir DG & Scott JM (2002) Impaired functioning of thermolabile methylenetetrahydrofolate reductase is dependent on riboflavin status: implications for riboflavin requirements. *Am J Clin Nutr* **76**, 436–441.
  48. McNulty H, Dowe LC, Strain JJ, Dunne A, Ward M, Molloy AM, McAnena LB, Hughes JP, Hannon-Fletcher M & Scott JM (2006) Riboflavin lowers homocysteine in individuals homozygous for the *MTHFR* 677C→T polymorphism. *Circulation* **113**, 74–80.
  49. McKinley MC, McNulty H, McPartlin J, Strain JJ & Scott JM (2002) Effect of riboflavin supplementation on plasma homocysteine in elderly people with low riboflavin status. *Eur J Clin Nutr* **56**, 850–856.
  50. Horigan G, Ward M, McNulty H, Purvis J, Strain JJ & Scott JM (2007). Riboflavin lowers blood pressure in patients with premature CVD homozygous for the methylenetetrahydrofolate reductase (*MTHFR*) C677T polymorphism. *Proc Nut Soc* **66**, 95A.
  51. Jacques PF, Selhub J, Bostom AG, Wilson PWF & Rosenberg IH (1999) The effect of folic acid fortification on plasma folate and total homocysteine concentrations. *N Eng J Med* **340**, 1449–1454.